Download PDF
Arthritis und Rheuma 2014; 34(01): 9-14
DOI: 10.1055/s-0037-1617969
Rheumatische Erkrankungen mit schwerem Verlauf
Schattauer GmbH

Welche Parameter beeinflussen die Prognose der rheumatoiden Arthritis?

Which parameters show an impact on the prognosis of rheumatoid arthritis?
H. Becker
1   Universitätsklinikum Münster, Innere Medizin D/Sektion Rheumatologie und Klinische Immunologie
,
P. Willeke
1   Universitätsklinikum Münster, Innere Medizin D/Sektion Rheumatologie und Klinische Immunologie
,
A. M. Jacobi
1   Universitätsklinikum Münster, Innere Medizin D/Sektion Rheumatologie und Klinische Immunologie
› Author Affiliations
Further Information

Publication History

Publication Date:
26 December 2017 (online)

    Permissions and Reprints

Zusammenfassung

Die rheumatoide Arthritis ist eine häufige entzündlich rheumatische Erkrankung mit artikulären und extraartikulären Manifestationen. Die Prognose der Erkrankung wird bestimmt durch die Aktivität der Erkrankung unter Berücksichtigung des Ansprechens auf die Therapie. Parameter wie der DAS28, der HAQ, das CRP, die BSG, serologische Befunde, bereits vorhandene Erosionen, Alter bei der Erstmanifestation und Geschlecht der Patienten zeigen einen Einfluss auf das Outcome. Diese Risikofaktoren sollten bei Diagnosestellung evaluiert werden. Nach ca. drei bis sechs Monaten sollten die klinischen Parameter und Laborparameter zur Abschätzung der Prognose erneut erfasst werden. Aber auch extraartikuläre Manifestationen und Komorbiditäten sollten berücksichtigt werden, denn sie haben ebenfalls einen Einfluss auf die Prognose und vor allem auf die Mortalität der Erkrankung und sind eine häufige Ursache für ein suboptimales Ergebnis bezüglich der antirheumatischen Langzeittherapie und der Therapieadhärenz.

Summary

Rheumatoid arthritis is a common inflammatory joint-disease going along with extraarticular manifestations. Prognosis is determined by the disease activity and response to treatment. Various parameters, such as DAS28, HAQ, CRP, ESR, serology, erosions, age at the time of diagnosis and gender influence the outcome. These risk factors should be evaluated when diagnosis is confirmed. After 3 to 6 months, clinical and laboratory measures should be assessed again to evaluate prognosis. But also extra-articular manifestations and co-morbidities should be considered since they show an impact on prognosis and mortality and are often responsible for suboptimal therapeutic results and lack of adherence.

Schlüsselwörter

Rheumatoide Arthritis - Prognose - Mortalität - Morbidität

Keywords

Rheumatoid arthritis - prognosis - mortality - morbidity
 

  • Literatur

  • 1 Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002; 16 (05) 707-722.
    CrossrefGoogle Scholar
  • 2 Verstappen SM, Symmons DP. What is the outcome of RA in 2011 and can we predict it?. Best Pract Res Clin Rheumatol 2011; 25 (04) 485-496.
    CrossrefGoogle Scholar
  • 3 Bombardier C, Barbieri M, Parthan A. et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis 2012; 71 (06) 836-844.
    CrossrefGoogle Scholar
  • 4 Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23 (05) (Suppl. 39) S14-S18.
    PubMedGoogle Scholar
  • 5 Olofsson T, Petersson IF, Eriksson JK. et al. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort. Ann Rheum Dis. 2013 Mar 21
    Google Scholar
  • 6 Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41 (06) 1072-1082.
    CrossrefGoogle Scholar
  • 7 Ziegler S, Huscher D, Karberg K. et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 2010; 69 (10) 1803-1808.
    CrossrefGoogle Scholar
  • 8 Baerwald C, Kneitz C, Bach M, Licht M. [Extra-articular manifestations of rheumatoid arthritis]. Z Rheumatol 2012; 71 (10) 841-849.
    CrossrefGoogle Scholar
  • 9 Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011; 25 (04) 469-483.
    CrossrefGoogle Scholar
  • 10 Maradit-Kremers H, Nicola PJ, Crowson CS. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52 (03) 722-732.
    CrossrefPubMedGoogle Scholar
  • 11 Doran MF, Crowson CS, Pond GR. et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46 (09) 2287-2293.
    CrossrefGoogle Scholar
  • 12 Baecklund E, Iliadou A, Askling J. et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54 (03) 692-701.
    CrossrefGoogle Scholar
  • 13 Fuchs HA, Kaye JJ, Callahan LF. et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16 (05) 585-591.
    Google Scholar
  • 14 Chung CP, Sokka T, Arbogast PG, Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006; 65 (12) 1653-1657.
    CrossrefGoogle Scholar
  • 15 Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol 2001; 28 (07) 1718-1722.
    Google Scholar
  • 16 McEntegart A, Morrison E, Capell HA. et al. Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56 (07) 410-413.
    CrossrefGoogle Scholar
  • 17 Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012; 41 (01) 1-9.
    Google Scholar
  • 18 Stanmore EK, Oldham J, Skelton DA. et al. Risk factors for falls in adults with rheumatoid arthritis: a prospective study. Arthritis Care Res (Hoboken) 2013; 65 (08) 1251-1258.
    CrossrefGoogle Scholar
  • 19 Amin S, Gabriel SE, Achenbach SJ. et al. Are young women and men with rheumatoid arthritis at risk for fragility fractures? A population-based study. J Rheumatol 2013; 40 (10) 1669-1676.
    CrossrefGoogle Scholar
  • 20 Ogdie A, Haynes K, Troxel AB. et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2012 Dec 21
    Google Scholar
  • 21 van Schaardenburg D, Hazes JM, de Boer A. et al. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993; 20 (01) 45-52.
    Google Scholar
  • 22 Dadoun S, Zeboulon-Ktorza N, Combescure C. et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013; 80 (01) 29-33.
    CrossrefGoogle Scholar
  • 23 Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21 (05) 907-927.
    CrossrefGoogle Scholar
  • 24 Peters MJ, Symmons DP, McCarey D. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69 (02) 325-331.
    CrossrefGoogle Scholar
  • 25 Furneri G, Mantovani LG, Belisari A. et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012; 30 (04) (Suppl. 73) S72-S84.
    Google Scholar
  • 26 Urata Y, Nakamura Y, Furukawa KI. Comparison of initial versus delayed introduction of a treat-to-target strategy in patients with recent-onset rheumatoid arthritis: results of the T-4 3-year study. Ann Rheum Dis. 2013 Jul 25
    Google Scholar
  • 27 Kievit W, Fransen J, de Waal Malefijt MC. et al. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford) 2013; 52 (08) 1500-1508.
    CrossrefGoogle Scholar
  • 28 Lassere MN, Rappo J, Portek IJ. et al. How many life years are lost in patients with rheumatoid arthritis? Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. Intern Med J 2013; 43 (01) 66-72.
    CrossrefGoogle Scholar
  • 29 Jacobsson LT, Turesson C, Nilsson JA. et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66 (05) 670-675.
    CrossrefGoogle Scholar
  • 30 Morgan CL, Emery P, Porter D. et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford). 2013 Oct 18
    Google Scholar
  • 31 Choi HK, Hernan MA, Seeger JD. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359 (9313): 1173-1177.
    CrossrefGoogle Scholar
  • 32 Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43 (01) 14-21.
    CrossrefPubMedGoogle Scholar
  • 33 Jamsen E, Virta LJ, Hakala M. et al. The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. Acta Orthop 2013; 84 (04) 331-337.
    CrossrefGoogle Scholar
  • 34 Callhoff J, Weiss A, Zink A, Listing J. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis. Rheumatology (Oxford) 2013; 52 (12) 2127-2135.
    CrossrefGoogle Scholar
  • 35 ter Wee MM, Lems WF, Usan H. et al. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis 2012; 71 (02) 161-171.
    CrossrefGoogle Scholar
  • 36 Scire CA, Verstappen SM, Mirjafari H. et al. Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2011; 63 (07) 945-952.
    CrossrefGoogle Scholar
  • 37 Puolakka K, Kautiainen H, Mottonen T. et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52 (01) 36-41.
    CrossrefGoogle Scholar
  • 38 Richman NC, Yazdany J, Graf J. et al. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore) 2013; 92 (02) 92-97.
    CrossrefGoogle Scholar
  • 39 Chen J, Shi Y, Wang X. et al. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol 2013; 2013: 406927.
    Google Scholar
  • 40 Tsuchiya Y, Takayanagi N, Sugiura H. et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011; 37 (06) 1411-1417.
    CrossrefGoogle Scholar
  • 41 Carmona L, Gonzalez-Alvaro I, Balsa A. et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003; 62 (09) 897-900.
    CrossrefGoogle Scholar
  • 42 Koivuniemi R, Paimela L, Suomalainen R. et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15 (04) 262-268.
    CrossrefGoogle Scholar
  • 43 Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 2013; 25 (03) 360-366.
    CrossrefGoogle Scholar
  • 44 Bartels C, Bell C, Rosenthal A. et al. Decline in rheumatoid vasculitis prevalence among US veterans: a retrospective cross-sectional study. Arthritis Rheum 2009; 60 (09) 2553-2557.
    CrossrefGoogle Scholar
  • 45 Ntatsaki E, Mooney J, Scott DG, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford). 2013 Oct 8
    Google Scholar
  • 46 Immonen K, Finne P, Gronhagen-Riska C. et al. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. Amyloid 2011; 18 (01) 25-28.
    CrossrefGoogle Scholar
  • 47 Kuroda T, Tanabe N, Kobayashi D. et al. Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis. J Rheumatol 2012; 39 (07) 1348-1354.
    CrossrefGoogle Scholar
  • 48 Westhoff G, Weber C, Zink A. [Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters]. Z Rheumatol 2006; 65 (06) 487-488 90-94, 96
    CrossrefGoogle Scholar
  • 49 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (05) 373-383.
    CrossrefGoogle Scholar
  • 50 Fries JF, Murtagh KN, Bennett M. et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50 (08) 2433-2440.
    CrossrefGoogle Scholar
  • 51 Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985; 290 (6484): 1797-1799.
    CrossrefGoogle Scholar
  • 52 Martinez MS, Garcia-Monforte A, Rivera J. Survival study of rheumatoid arthritis patients in Madrid (Spain). A 9-year prospective follow-up. Scand J Rheumatol 2001; 30 (04) 195-198.
    CrossrefGoogle Scholar
  • 53 Strangfeld A, Eveslage M, Schneider M. et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70 (11) 1914-1920.
    CrossrefGoogle Scholar
  • 54 Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011; 13 (04) R139.
    CrossrefPubMedGoogle Scholar
  • 55 Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64 (09) 2847-2855.
    CrossrefGoogle Scholar
  • 56 Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK. et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010; 69 (07) 1333-1337.
    CrossrefGoogle Scholar
  • 57 Laakso M, Mutru O, Isomaki H, Koota K. Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis. Ann Rheum Dis 1986; 45 (08) 663-667.
    CrossrefGoogle Scholar
  • 58 Bieber V, Cohen AD, Freud T. et al. Autoimmune smoke and fire - coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: a cross-sectional analysis. Immunol Res 2013; 56 (2-3): 261-266.
    CrossrefGoogle Scholar
  • 59 Boyer JF, Gourraud PA, Cantagrel A. et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011; 78 (02) 179-183.
    CrossrefGoogle Scholar